In general, these results suggest that the camrelizumab plus albumin-bound paclitaxel regimen was significantly more effective than camrelizumab monotherapy as a third- or later-line regimen for advanced NSCLC patients. This evidence concerns the gene ALB and non-small cell lung carcinoma.